FDA’s Recent Letter to Pathway Genomics

The FDA’s Recent untitled letter to Pathway Genomics regarding their alleged direct-to-consumer marketing of the CancerIntercept^TM Detect highlights the increased scrutiny facing lab-developed tests.

More information can be found here. The letter itself can be found here.